Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Bmi-1 is overexpressed in colorectal cancer (CRC), presenting a potential therapeutic target.
• Developing novel agents to inhibit Bmi-1 is crucial for effective CRC treatment.

Purpose of the Study:

• To synthesize and evaluate novel cyanoenone-modified diterpenoid analogs for antiproliferative activity against CRC.
• To identify potent Bmi-1 inhibitors with improved selectivity and reduced toxicity.

Main Methods:

• Synthesis of novel diterpenoid analogs.
• In vitro antiproliferative assays against CRC cell lines.
• Bmi-1 inhibitory activity assessment.
• Selectivity index (SI) determination using normal human fibroblasts (HAF).
• In vitro assays including polycomb repressive complex 1 (PRC1) complex, transwell migration, colony formation, cancer stem cell proliferation, and apoptosis.
• In vivo antitumor efficacy study in HCT116 tumor-bearing mice.

Main Results:

• Most synthesized compounds displayed significant antiproliferative and Bmi-1 inhibitory activity.
• Compound 33 (SH498) exhibited superior antiproliferative effects compared to the positive control PTC-209.
• Compound 33 demonstrated high selectivity for CRC cells over normal HAF cells (SI 7.3-13.1).
• Compound 33 showed promising results in various in vitro assays and in vivo antitumor studies.

Conclusions:

• Novel diterpenoid analogs, particularly compound 33 (SH498), are potent inhibitors of Bmi-1 and exhibit significant antiproliferative activity against CRC.
• Compound 33 represents a promising therapeutic candidate for colorectal cancer due to its efficacy, selectivity, and favorable safety profile.
• Further investigation of compound 33 is warranted for its clinical development in CRC treatment.